Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecfidera Effect on Gut Microbiota in RRMS
NCT02471560Phase 4Completed
- Sponsor
- Biogen
- Start
- Nov 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoint: Change in gut microbiota composition in participants pre vs. post initiation of DMF treatment at Week 12. Started Nov 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02471560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471560.